Diffuse malignant peritoneal mesothelioma isn’t a great radiation target so fortunately this small series reports a 4/19 (21%) achieved a partial response and 10/19 (53%) stable disease with pembrolizumab monotherapy regardless of PD-L1 expression. | Marmarelis, JAMA Netw Open 2023
